Symbol="OCX"
AssetType="Common Stock"
Name="OncoCyte Corp"
Description="OncoCyte Corporation, a molecular diagnostics company, researches, develops, and markets proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company is headquartered in Irvine, California."
CIK="1642380"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES"
Address="1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="28761300"
EBITDA="-22905000"
PERatio="None"
PEGRatio="0"
BookValue="5.78"
DividendPerShare="0"
DividendYield="0"
EPS="-1.8"
RevenuePerShareTTM="0.173"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.149"
ReturnOnEquityTTM="-0.184"
RevenueTTM="875000"
GrossProfitTTM="188000"
DilutedEPSTTM="-1.8"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.218"
AnalystTargetPrice="5.81"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="6.13"
PriceToBookRatio="0.648"
EVToRevenue="2.608"
EVToEBITDA="-0.362"
Beta="1.571"
num_52WeekHigh="22"
num_52WeekLow="3.48"
num_50DayMovingAverage="4.225"
num_200DayMovingAverage="6.79"
SharesOutstanding="8241000"
DividendDate="None"
ExDividendDate="None"
symbol="OCX"
open="3.51"
high="3.73"
low="3.49"
price="3.49"
volume="15070.00"
latest_trading_day="2023-08-11"
previous_close="3.51"
change="-0.02"
change_percent="-0.5698%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="98"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="2"
Volume_recent_avg="290850"
Change_recent_avg="-0.01"
Delta_recent_avg="0.06"
Variance_recent_avg="0.03"
Change_ratio_recent_avg="-0.49"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="2"
Aroon_momentum_negative="98"
image_negative_thumbnail_id_1="1114"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0147.jpeg"
image_negative_thumbnail_id_2="1119"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0152.jpeg"
image_neutral_thumbnail_id_1="586"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0013.jpeg"
image_neutral_thumbnail_id_2="541"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0058.jpeg"
image_positive_thumbnail_id_1="673"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0035.jpeg"
image_positive_thumbnail_id_2="971"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0133.jpeg"
image_professor_thumbnail_id_1="1202"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0036.jpeg"
image_professor_thumbnail_id_2="1171"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0005.jpeg"
